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Following Coronary Stenting*
Robert W. Yeh, MD,y Laura Mauri, MD,z Dean J. Kereiakes, MDxSEE PAGE 777A dverse ischemic events following coronarystenting may be related to either stented ornonstented vascular segments. Although
dual antiplatelet therapy (DAPT) improves clinical
outcomes following coronary stent deployment
through reductions in both stent thrombosis (ST) as
well as myocardial infarction (MI) not related to ST,
the optimal duration of DAPT following either drug-
eluting stent (DES) or bare-metal stent (BMS) deploy-
ment has been the subject of debate. Current U.S.
clinical practice guidelines recommend at least
1 year of therapy, if tolerated, following DES in stable
ischemic heart disease and at least 1 year of therapy
following stenting in acute coronary syndromes
regardless of stent type (DES or BMS) (1). The beneﬁt
of DAPT must be weighed against the risk of bleeding,
which is increased in proportion to the intensity and
duration of treatment. Multiple randomized trials
have compared different durations of DAPT following
coronary stenting (2–7). Although these trials differ in
their design, the populations enrolled, and durations
of therapy, they share the common feature of having
been underpowered to detect clinically-meaningful*Editorials published in the Journal of the American College of Cardiology
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REVA Medical.differences in ST and MI, as evidenced by the wide
conﬁdence intervals for these endpoints (Table 1).
As a result, most studies have combined safety
(bleeding) and efﬁcacy (ischemia) measures into a
single composite primary endpoint in an attempt to
accrue power for the assessment of noninferiority
between DAPT treatment durations (4–7). This tactic,
which obscures directionally divergent changes in
measures of different relative value, may confound
the ability to draw accurate conclusions.The ITALIC (Is There A Life for DES After Discon-
tinuation of Clopidogrel) study, which appears in
this issue of the Journal (8), randomly assigned
1,850 aspirin-responsive subjects who were free from
death, MI, or target vessel revascularization at
6 months following everolimus-eluting stent (EES)
(Xience, Abbott Vascular, Santa Rosa, California; or
Promus, Boston Scientiﬁc, Marlborough, Massachu-
setts) deployment to receive either continued dual
therapy (aspirin plus a P2Y12 receptor inhibitor) or
aspirin only for an additional 18 months (a total of
24 months) on an unblinded basis. Although the
stated DAPT duration comparison was 6 months
versus 24 months, the trial primary endpoint of
death, MI, urgent target vessel revascularization,
stroke, or major bleeding event was assessed at
12 months and was observed in 1.6% versus 1.5% of
the 6-month versus 12-month treatment groups,
respectively (p ¼ 0.85, p < 0.001 for noninferiority).
The authors conclude that 6-month DAPT is non-
inferior to longer duration treatment. However,
multiple concerns cloud the interpretation of this
conclusion.
First, a lack of power (study was terminated early
due to poor enrollment), lower-than-expected event
rates (the primary endpoint event rate was antici-
pated to be 3%), and imbalanced study medication
TABLE 1 Randomized Trials of Dual Antiplatelet Treatment Duration After DES
Trial Name (Ref. #)
Total
Randomized
Treatment
Duration DES Type Stent Thrombosis
Myocardial
Infarction Bleeding
REAL þ ZEST LATE (2) 2,701 24 vs. w12 SES, ZES, or PES 1.23 (0.33–4.58) 1.41 (0.54–3.71) 2.96 (0.31–28.46)
PRODIGY (4) 1,357 24 vs. 6 PES, ZES, or EES 0.87 (0.41–1.81) 0.94 (0.61–1.45) 2.17 (1.44–3.22)
EXCELLENT (3) 1,443 12 vs. 6 SES or EES 0.17 (0.02–1.39) 0.54 (0.21–1.35) 2.0 (0.37–11.11)
OPTIMIZE (5) 3,120 12 vs. 3 ZES 0.95 (0.42–2.04) 0.85 (0.57–1.29) 1.41 (0.63–3.13)
ITALIC (8) 1,850 12 vs. 6 EES 0 vs. 3 events* 0.67 (0.19–2.38) 3 vs. 0 events*
ISAR-SAFE (7) 4,005 12 vs. 6 EES, SES, ZES, or BES 0.80 (0.21–3.03) 1.08 (0.51–2.27) 1.25 (0.34–4.76)
DAPT (10) 9,961 30 vs. 12 EES, ZES, SES, or PES 0.29 (0.17–0.48) 0.47 (0.37–0.61) 1.61 (1.21–2.16)
Values are n or hazard ratio (95% conﬁdence interval). *Due to 0 events in 1 arm, hazard ratio could not be estimated.
BES ¼ biolimus-eluting stent(s); DAPT ¼ dual antiplatelet therapy; DES ¼ drug-eluting stent(s); EES ¼ everolimus-eluting stent(s); EXCELLENT ¼ Efﬁcacy of XIENCE/
PROMUS versus CYPHER to reduce late loss after stenting; ISAR-SAFE ¼ The intracoronary stenting and antithrombotic regiment: Safety and efﬁcacy of 6 months dual an-
tiplatelet therapy after drug-eluting stenting; ITALIC ¼ Is There A Life for DES After Discontinuation of Clopidogrel; OPTIMIZE ¼ Optimized duration of clopidogrel therapy
following treatment with the zotarolimus-eluting stent in real-world clinical practice; PES ¼ paclitaxel-eluting stent; PRODIGY ¼ Prolonging dual antiplatelet treatment after
grading stent-induced intimal hyperplasia; REALþZEST LATE ¼ Correlation of clopidogrel therapy discontinuation in real-world patients treated with drug-eluting stent im-
plantation and late coronary arterial thrombotic events þ evaluation of the long-term safety after zotarolimus-eluting stent, sirolimus-eluting stent or paclitaxel-eluting stent
implantation for coronary lesions - late coronary arterial thrombotic events; SES ¼ sirolimus-eluting stent(s); ZES ¼ zotarolimus-eluting stent(s).
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788compliance (24% of short-duration subjects were
nonadherent vs. 5.4% of long-duration subjects) all
bias toward the null for noninferiority. Second, the
95% conﬁdence interval surrounding the primary
endpoint is wide, allowing for a >2-fold increase in
events in the short-duration treatment group without
negating the noninferiority claim. Third, few events
were observed (only 3 [0.16%] STs and 10 [0.45%]
MIs), which suggests that the study population was
very low risk and perhaps not representative of
routine clinical practice. The prerequisite require-
ment for documented ex vivo platelet responsiveness
to aspirin prior to randomization may have contrib-
uted to the lower-than-expected event rates. The
ITALIC study is novel with respect to this exclu-
sionary (aspirin nonresponsiveness) criterion.
Finally, given the low event rates and sample size
in the primary analysis, the subgroup analysis of
acute coronary syndrome patients is grossly under-
powered to examine potential treatment interactions.
Although it may be tempting to combine the ITALIC
study with prior trials using meta-analysis, the
post hoc aggregation of underpowered trials with
variable study populations, protocols, methodol-
ogies and endpoints not infrequently provides results
that are proven incorrect by a subsequent,
adequately-powered, randomized, controlled clinical
trial (9).
In this context, the DAPT (Dual Antiplatelet Ther-
apy) study, designed in response to a request from
the U.S. Food and Drug Administration, is adequately
powered for the efﬁcacy coprimary endpoints of
ST (Academic Research Consortium deﬁnite/probable
deﬁnition) and major adverse cardiovascular and
cerebrovascular events (composite occurrence ofdeath, MI or stroke), as well as a primary safety
endpoint of severe/moderate (GUSTO deﬁnition)
bleeding (10). Following 1 year of DAPT, subjects who
had received treatment with a U.S. Food and Drug
Administration–approved DES (Xience/Promus EES;
Taxus paclitaxel-eluting stent from Boston Scientiﬁc;
Cypher sirolimus-eluting stent [SES] from Cordis,
Fremont, California; or Endeavor zotarolimus-eluting
stent from Medtronic, Santa Rosa, California) or
BMS, who were free from ischemic cardiovascular
events and severe/moderate bleeding, and who were
adherent to antiplatelet therapy were randomly
assigned to receive either thienopyridine (clopidogrel
or prasugrel) in combination with aspirin or aspirin
plus matching placebo on a blinded basis for an
additional 18 months. This 18-month period on a
randomized, blinded study drug was followed by a
mandatory 3-month observation period without
thienopyridine therapy for all subjects. Among DES-
treated subjects (n ¼ 9,961) prolonged thienopyr-
idine therapy for 30 months was associated with a
71% relative reduction in ST and a 29% relative
reduction in major adverse cardiovascular and cere-
brovascular events (p < 0.001), which was driven by a
53% relative reduction in MI (p < 0.001), 55% of which
was not attributable to ST. Bleeding events were
increased by 61% (p ¼ 0.001) and were largely due to
moderate bleeding. Severe bleeding events, including
fatal events, were rare and were not different be-
tween groups.
Importantly: 1) adverse ischemic events were
observed with increased frequency in the 3 months
following thienopyridine discontinuation in both
treatment arms: (i.e., 12 to 15 months for the placebo
group and 30 to 33 months in the continued
FIGURE 1 Ischemic Events in the Dual Antiplatelet Therapy Study Primary Analysis
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Stent thrombosis and myocardial infarction during the primary analysis period (12 to
30 months) and following study drug discontinuation (30 to 33 months). The randomized
study drug treatment (thienopyridine vs. placebo) was administered during months 12 to
30. During months 12 to 15, an increased ischemic risk was observed for patients ran-
domized to placebo as thienopyridine therapy was withdrawn. During months 3 to 33,
increased risk was observed for patients randomized to extended thienopyridine therapy as
thienopyridine was withdrawn. All subjects received aspirin. *Subjects randomized at
12 months and discontinued study drug at 30 months.
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789thienopyridine group); and 2) the time to event
curves for ST and MI continued to diverge
throughout the randomized treatment period (12 to
30 months) (Figure 1). These observations suggest: 1)
the preventive beneﬁt of thienopyridine therapy is
realized early; 2) treatment duration beyond 30
months may provide additional ischemic beneﬁt; and
3) treatment discontinuation may be associated with
ischemic hazard even months to years after coronary
stenting. This ongoing risk of cardiovascular events
beyond the stented segment should not be surprising
in subjects with symptomatic coronary artery dis-
ease. Finally, adjusted analyses demonstrated that
the magnitude of beneﬁt associated with longer
(30 months) duration of thienopyridine for reduction
in ST or MI was consistent across all 4 DES types
studied, including the 4,703 (47.2%) subjects who
received EES similar to what was exclusively utilized
in the ITALIC study (10). Speciﬁcally, adjusted
hazard ratios favoring longer duration therapy in
EES-treated patients were 0.38 (95% conﬁdence in-
terval: 0.15 to 0.97) for ST and 0.63 (95% conﬁdence
interval: 0.44 to 0.91) for MI.
Thus, although the absolute risk of ST may be less
with new-generation DES (11), treatment beneﬁt
persists well after the initial procedure, and the
hazard of MI not related to ST remains ongoing and
is modiﬁed by extended DAPT duration. Although
the relative risk reductions for ST and MI observed
in the DAPT study are dramatic, particularly in the
context that subjects were not randomized until
1 year following their index procedure, one might
expect these differences to be magniﬁed if the
12-month treatment group had been of even shorter
duration, as was examined in the ITALIC study.
Such differences would only be detectable in an
appropriately-powered trial that enrolled subjects
representative of current percutaneous coronary
intervention practice (not smaller trials of low-risk
subjects).
The decision to continue DAPT beyond any time
point must involve a balance of risks (12). The risk
of bleeding must not be discounted, despite the
magnitude of antithrombotic beneﬁts (often nonstent
related) observed in the DAPT study. However, recentcalls to “individualize” therapy provide insufﬁcient
guidance for practicing clinicians (13). Among pa-
tients without prior episodes of severe/moderate
bleeding who tolerated DAPT to 1 year, signiﬁcant
ischemic event beneﬁt is accrued by extending DAPT
through 30 months if not longer. In this context, the
bleeding risk appears to be acceptable. Finally,
further analyses are required to provide risk stratiﬁ-
cation for the purpose of safe discontinuation of
DAPT beyond 30 months of treatment.
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